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Abstract
An important virulence strategy evolved by bacterial pathogens to overcome host defenses is the modulation of host cell
death. Previous observations have indicated that Yersinia pestis, the causative agent of plague disease, exhibits restricted
capacity to induce cell death in macrophages due to ineffective translocation of the type III secretion effector YopJ, as
opposed to the readily translocated YopP, the YopJ homologue of the enteropathogen Yersinia enterocolitica O:8. This led
us to suggest that reduced cytotoxic potency may allow pathogen propagation within a shielded niche, leading to
increased virulence. To test the relationship between cytotoxic potential and virulence, we replaced Y. pestis YopJ with
YopP. The YopP-expressing Y. pestis strain exhibited high cytotoxic activity against macrophages in vitro. Following
subcutaneous infection, this strain had reduced ability to colonize internal organs, was unable to induce septicemia and
exhibited at least a 10
7-fold reduction in virulence. Yet, upon intravenous or intranasal infection, it was still as virulent as the
wild-type strain. The subcutaneous administration of the cytotoxic Y. pestis strain appears to activate a rapid and potent
systemic, CTL-independent, immunoprotective response, allowing the organism to overcome simultaneous coinfection with
10,000 LD50 of virulent Y. pestis. Moreover, three days after subcutaneous administration of this strain, animals were also
protected against septicemic or primary pneumonic plague. Our findings indicate that an inverse relationship exists
between the cytotoxic potential of Y. pestis and its virulence following subcutaneous infection. This appears to be
associated with the ability of the engineered cytotoxic Y. pestis strain to induce very rapid, effective and long-lasting
protection against bubonic and pneumonic plague. These observations have novel implications for the development of
vaccines/therapies against Y. pestis and shed new light on the virulence strategies of Y. pestis in nature.
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Introduction
The genus Yersinia is comprised of three human pathogens: Y.
pestis, Y. pseudotuberculosis, and Y. enterocolitica. Yersinia pestis is the
causative agent of plague, an acute and often fatal disease [1].
Bubonic plague, which develops following a bite by an infected
flea, and pneumonic plague, which ensues from inhaled bacterial
aerosol, are two forms of the disease. Y. enterocolitica and Y.
pseudotuberculosis are fecal-oral enteropathogens that cause invasive
gastrointestinal diseases that are usually overcome by the host. The
three pathogenic Yersinia species share a common type III secretion
system (TTSS) that is essential for virulence. The TTSS system is
encoded by a 70 kb plasmid and its production is induced by
temperature elevation to 37uC. It interacts with the eukaryotic
host cell [2] to form a translocation apparatus for injecting effector
proteins into the cytosol. These effector proteins, known as Yersinia
outer proteins (Yops), act to down-regulate host defense mecha-
nisms. The major known effects of Yops are counteraction of host
innate immune cell function such as pathogen ingestion and
destruction within the phagosome, induction of pro-inflammatory
cytokines and subsequent stimulation of the adaptive immune
system [3]. Numerous studies have shown that the major
mechanism of action of Yop effector proteins is the disruption of
the target cell signaling network and cytoskeleton rearrangement,
which are necessary for phagocytosis by host macrophages and
polymorphonuclear neutrophils. These effects involve the action of
several Yops including YopE, YopH, YopO/YpkA and YopT
[4,5]. One of the Yops, YopJ (named YopP in Y. enterocolitica) was
shown to induce apoptotic cell death in Yersinia-infected macro-
phages in vitro [6–10] as well as in animal models of infection [11–
13]. Induction of the apoptotic process was found to occur through
the inhibition of NF-kB activation [14,15] and MAPK signaling
pathways [16–18], along with the activation of caspase pathways
[10,11,19,20]. These effects influence both inflammatory capacity
and apoptosis of host immune cells.
It has been suggested that YopJ belongs to a family of proteases
related to the ubiquitin-like protein proteases [21]. In line with this
proposition, YopJ was shown to be a deubiquitinating cysteine
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5938protease capable of removing ubiquitin moieties from IkBa,
thereby inhibiting its proteasomal degradation and leading to the
down-regulation of NF-kB functions [22]. In addition, YopJ was
recently demonstrated to acetylate Ser/Thr residues in the
activation loop of MAPK kinases (MKKs) and IkB kinases (IKKs),
consequently preventing their activation by phosphorylation
[23,24]. This newly identified acetyltransferase activity of YopJ
may well account for its ability to inhibit MAPK pathways and
NF-kB activation. It is noteworthy that current knowledge on the
interactions between Yersinia and innate immune cells is mostly
based on studies with Yersinia enteropathogenic species. Yet, in
spite of the high homology between the effectors and the
translocation apparatuses of these species and those of Y. pestis,i t
appears that certain mechanisms for evading host innate immunity
differ between them. We have demonstrated that Y. pestis has a
limited ability to induce programmed cell death in infected
macrophages compared to Y. enterocolitica 0:8 serotype [10,25].
This observation was found to correlate with downgraded
translocation of YopJ from Y. pestis to the target cell [10].
Similarly, whereas interactions of Y. enterocolitica 0:8 with dendritic
cells (DCs) lead to YopP-mediated induction of apoptotic cell
death, infection of DCs with Y. pestis failed to affect cell viability
[26,27]. The difference in secretion levels of Y. pseudotuberculosis
YopJ and Y. enterocolitica 0:8 YopP was recently attributed to N-
terminal sequence polymorphism between the proteins [13], and
could also explain the limited secretion of Y. pestis YopJ.
The role of YopJ/YopP effectors in the in vivo virulence of
enteropathogenic Yersinia is still uncertain. Several studies have
reported impaired virulence of Y. pseudotuberculosis yopJ mutants
[12,13] and a Y. enterocolitica yopP mutant [28] in mouse models.
However, others have reported that yopJ deletion had no effect on
Y. pseudotuberculosis virulence [29]. The role of Y. pestis YopJ in
pathogenesis was examined in several mouse models in which it
was found to be dispensable for virulence. The LD50 of a Y. pestis
pgm
2 yopJ mutant following intravenous (i.v.) infection was only
slightly higher (1.5-fold) than that of the parental strain [30]. In
addition, a recent study in a rat model of bubonic plague has
shown that YopJ was not essential for the manifestation of
virulence [11]. Similar results were obtained in a mouse model of
bubonic plague using a yopJ deletion mutant of the Kimberley53
strain [25].
Accumulating evidence seems to indicate that the ability to
destroy host immune cells is not essential for the manifestation of
virulence in Y. pestis. Moreover, the presence of viable infected
immune cells at the infection site may rather allow the invading
pathogen to replicate inside a shielded niche provided by the host
cells. Given the fact that Y. pestis is found intracellularly during the
early stages of infection [31,32] and can replicate within
macrophages [32,33], one may assume that effective apoptotic
activity against immune cells might impair its survival in vivo. The
observation that Y. pestis demonstrates restricted capacity to induce
apoptosis in macrophages and DCs, along with the finding that
YopJ is not essential for Y. pestis virulence, led us to suggest that
reduced apoptotic potency may have contributed to the highly
pathogenic phenotype of Y. pestis [10].
In the present study, we challenged this assumption using the
highly virulent Y. pestis Kimberley53, its yopJ deletion mutant and
progeny derivatives expressing in trans either the Y. pestis YopJ or
the YopP of Y. enterocolitica 0:8. We demonstrate that while the
YopP-expressing strain acquires potent apoptotic/cytotoxic capa-
bility against host macrophages, it appears to be less virulent than
the parental or wild-type strains in the mouse model of bubonic
plague (subcutaneous infection). However, the Y. pestis-YopP
engineered strain is indistinguishable in its virulence in the
septicemic or pneumonic mouse infection models (intravenous or
intranasal administration, respectively). The inverse relationship
between the cytotoxicity of YopP-expressing Y. pestis and its
virulence following subcutaneous infection appears to also be
associated with its ability to induce very rapid, effective and long-
lasting immunoprotection against bubonic and pneumonic plague.
Results
Y. pestis overexpressing YopP is avirulent following
subcutaneous administration to mice
Expression of YopP, the YopJ homologue in Y. enterocolitica O:8,
in the background of the attenuated Y. pestis EV76 strain was
previously shown to render this strain highly cytotoxic to J774A.1
and RAW 264.7 macrophage cells [10]. In order to explore
whether enhanced cytotoxic potency would attenuate Y. pestis
virulence, in this study, we used the highly virulent yopJ-deleted
strain of Y. pestis Kimberley53 (Kim53DJ) [25] to generate
recombinant strains expressing in trans either YopP (Kim53DJ+P)
or YopJ (Kim53DJ+J) (Table 1). Plasmid construction was based
on replacing the green fluorescent protein (GFP) gene from the
pUC19 derivative plasmid pGFPuv by yopP or yopJ genes, under
the control of the lac promoter. As a control, we used wild-type
Kim53 carrying the same expression vector with the gfp gene
(Kim53pGFP). As was shown in the past with the attenuated
EV76-based strains [10], the newly constructed Kim53-derived
strains exhibited expression levels comparable to those of the two
homologous effectors (YopJ and YopP), but with pronounced
differences in induction of cell death upon infection of macro-
phages. Expression of YopP conferred high cytotoxic potential,
which expression of YopJ did not (Figure 1A, upper lanes and 1B).
It should be noted that expression of YopJ/P had no apparent
effect on the bacterial growth rate in vitro (Figure 1C).
The impact of increased cytotoxicity on Y. pestis virulence was
tested initially by subcutaneous (s.c.) infection of mice. Mice
infected with 100 colony forming units (cfu) of Kim53DJ+P
(equivalent to 100 LD50 of wild type Kim53) exhibited 100%
survival, as opposed to 100% mortality in mice infected with an
identical dose of the control Kim53pGFP or the wild-type Kim53
strain (Figure 1D). The effect of YopP expression was so dramatic
that even after infection with 1610
6 cfu of Kim53DJ+P, all
animals survived (Figure 1D). These results were observed with
two independent isolates of Kim53DJ+P. Increasing the infection
dose of Kim53DJ+Pt o1 0
7 cfu resulted in 75% survival, indicating
that the Kim53DJ+PL D 50 value is above 10
7 cfu. At the same
time, the less cytotoxic strain over-expressing YopJ (Kim53DJ+J;
Figure 1B) remained virulent, as reflected by the mortality of
infected mice (Figure 1D) and the calculated LD50 value of 1 cfu.
It should be noted that Kim53pGFP had similar LD50 as Kim53,
however, the former had some delay in mean time to death (from
3 to 4.4 days, P,0.01).
All of the tested Kim53-derived Y. pestis strains carry the pMT1,
pCD1, pPCP1 plasmids and the pgm locus, and preserved the
functionality of their TTSS, as manifested by their calcium-
dependent growth at 37uC. In addition, YopP expression had no
apparent effect on the expression of other Y. pestis Yop effectors
such as YopE (Figure 1A, lower lanes). Consistent with our in vitro
observations, the YopP-expressing Y. pestis strain induced signif-
icantly higher levels of apoptosis in infected spleen cells compared
to the virulent Kim53pGFP strain, as determined by staining with
anti-active caspase-3 antibodies (Figure 1E). It therefore appears
that concomitant with YopP-mediated enhanced cytotoxicity, the
Y. pestis bacteria expressing YopP exhibit reduced virulence in the
bubonic plague model.
Protection by Cytotoxic Y. pe
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colonization of internal organs
Host immune cells may serve in vivo as a favorable intracellular
niche and a shielding vehicle for plague bacilli [31,32,33]. It was
therefore interesting to determine whether the avirulent phenotype
of Kim53DJ+P is associated with the cytotoxic effect of YopP
through interference with bacterial propagation and delivery to
internal tissues. Accordingly, we monitored the colonization of
internal organs by Kim53DJ+P compared to the Y. pestis
Kim53pGFP control strain. Mice were subcutaneously infected
with 1610
4 cfu of each strain. Dissemination to draining inguinal
lymph nodes (ILNs), the spleen and blood was examined 60 hours
post-infection, a time point representing terminal stages of disease
in Kim53pGFP-infected mice that served as controls. The number
of colony forming units in the ILNs and the spleen of mice infected
with Kim53DJ+P was about 100-fold lower than with the control
Y. pestis strain (Figure 2). An even more pronounced disparity was
observed in blood. Kim53DJ+P could not be detected in blood
whereas the Y. pestis control strain reached an average concentra-
tion of 1610
6 cfu/ml. Interestingly, despite the fact that
colonization of the spleen in Kim53DJ+P-infected mice reaches
substantial bacterial count (1610
5 bacteria per spleen), the
infection with high dose of Kim53DJ+P is not lethal (Figure 1D).
Kim53DJ+P is highly virulent when administered through
the intravenous or intranasal routes
In an attempt to gain deeper insight into the mechanisms
involved in the observed attenuation of virulence of the
Kim53DJ+P strain, mice were infected with 2,000 cfu intrave-
nously (i.v.), thereby bypassing the subcutaneous barrier. Under
these conditions, both Y. pestis strains, the YopP-expressing strain
and the Kim53pGFP strain, caused 100% mortality with
comparable mean time to death (MTTD) of 3.2 and 3.4 days,
respectively (Figure 3A).
In view of these results, it became interesting to examine
whether Kim53DJ+P would also exhibit an attenuated phenotype
under the conditions of respiratory infection. Since the role of Y.
pestis YopJ in the development of primary pneumonic plague has
not yet been examined, we first compared the virulence of
Kim53DJ to that of wild-type Kim53 using intranasal (i.n.)
infection of mice. Both strains demonstrated identical LD50 values
(ca. 550 cfu), consistent with the results obtained with other
virulent wild-type Y. pestis strains harboring an intact yopJ [34,35].
This finding indicates that YopJ is not essential for virulence via
the airways route.
In experiments aimed at assessing the respiratory virulence of
Kim53DJ+P, it was found that all mice infected intranasally with
6610
4 cfu of Kim53DJ+P (equivalent to ,30 LD50 of the wild-
type strain), died within four days at the same rate as those infected
intranasally with the virulent control strain Kim53pGFP
(Figure 3B). In addition, both strains demonstrated the same i.n.
LD50 value of 1,800 cfu, which is comparable to that of the
parental Kim53 and Kim53DJ strains. Moreover, disease
progression and systemic bacterial dissemination, as reflected by
bacterial cfu counts in the lungs, mediastinal lymph nodes
(MSLNs), spleen and blood, were also comparable (Figure 3C).
It may be of interest to note in this context that macrophages from
alveolar origin (MH-S) were found to be more resistant to the
cytotoxic effect induced by Kim53DJ+P (reduction of 80% in cell
death upon infection with 10 MOI) compared to J774A.1
macrophage cells.
The non-virulent phenotype of Kim53DJ+P is dominant
over the virulent phenotype of Kim53pGFP in
subcutaneous co-infections
One possible explanation for the reduced infectivity and spread
of Kim53DJ+P following s.c infection is that this strain kills the
transporter immune cells and thus prevents dissemination. An
alternative explanation is that these bacteria induce a rapid and
efficient protective immune response that eliminates the bacteria
from the bloodstream and accounts for the attenuated virulence
phenotype.
To clarify this issue, we co-infected mice subcutaneously with
Kim53DJ+P and the virulent Kim53pGFP strain (Table 2).
Indeed, co-infection with Kim53DJ+P could completely protect
animals from 10, 100 and even 10,000 LD50 of the virulent
Kim53pGFP strain. Such protection could be achieved as long as
the ratio of Kim53DJ+P to Kim53pGFP was at least 10:1.
Lowering the ratio between the two strains to 1:1 decreased the
extent of protection (Table 2). Such protection against subcuta-
neous infection with Kim53pGFP could not be provided by co-
infection with different attenuated Y. pestis strains such as
Table 1. Bacterial strains and plasmids used in this study.
Strains and plasmids Relevant characteristics Reference or source
Y. pestis strains
Kim53 Virulent, Kimberley53 [55]
Kim53DJ Kim53 deleted for yopJ [25]
Kim53pGFP Kim53 carrying pGFPuv This study
Kim53DJ+P Kim53DyopJ carrying pYopP This study
Kim53DJ+J Kim53DyopJ carrying pYopJ This study
Kim53Dp70Dp10 Spontaneously pPCP1- and pCD1-cured Kim53 [51]
EV76 pgm
2 (Girard’s strain) [56]
EV76DJ+PE V 7 6 DyopJ carrying pYopP [10]
Plasmids
pGFPuv Lac-controlled gfp gene on pUC vector; Amp
R CLONTECH, USA
pYopP pGFPuv in which gfp gene was replaced by Y. enterocolitica O:8 yopP gene [10]
pYopJ pGFPuv in which gfp gene was replaced by Y. pestis Kimberley53 yopJ gene [10]
doi:10.1371/journal.pone.0005938.t001
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PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e5938Figure 1. Expression of YopP in Y. pestis enhances its cytotoxicity in macrophages and reduces its virulence. (A) Assessment of bacterial
YopJ/P expression. Y. pestis recombinant strains were grown for 3 hrs at 37uC. Western blot analysis was conducted with anti-YopJ/P antibodies
(upper lane) or anti-YopE antibodies (lower lane). Endogenous YopJ expression in both wild-type Kim53 and Kim53pGFP strains could be detected
only under non-standard conditions of considerably longer exposure time (data not shown). (B) Cytotoxic effect of Y. pestis recombinant strains on
J774A.1 macrophage cell line. Cells were infected with Kim53pGFP (circle), Kim53DJpGFP (X symbol), Kim53DJ+J (square) and Kim53DJ+P (triangle) at
the indicated MOIs for 1 hour. Cell death was determined by LDH release test. (C) Growth curves of Kim53pGFP (circle), Kim53DJ+J (square) and
Kim53DJ+P (triangle). Bacteria were inoculated to OD630 0.005 in heart infusion broth-containing microplate wells and incubated in a plate reader
(Sunrise, Tecan) for an additional 22 hrs at 28uC. (D) Attenuation of YopP-expressing Y. pestis recombinant strain. Groups of mice were infected
subcutaneously with 1610
2 cfu of Kim53 (10 mice per group, white diamond), Kim53pGFP (5 mice per group, black circle) or Kim53DJ+J (5 mice per
group, white square), or with 1610
6 cfu of Kim53DJ+P (5 mice per group, white triangle). Mortality rates were followed daily for 14 days after
infection. (E) Spleen sections, isolated from mice 48 hrs after s.c. infection with 1610
4 cfu of Kim53pGFP or Kim53DJ+P, stained with anti-active
caspase-3 antibodies (left panel). Scale bar=50 mm. The arrow head indicates apoptotic cells. Caspase-positive cells in at least 20 random non-
overlapping microscopic fields (magnification, 61000) were counted (three mice per group, right panel).
doi:10.1371/journal.pone.0005938.g001
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whether the Kim53DJ+P-mediated resistance to lethal infection
with Kim53 is a systemic or a localized effect, the animals were
simultaneously infected at separate sites, with each site inoculated
subcutaneously with a different strain. As shown in Figure 4B,
even under conditions of distant s.c inoculation sites, the ability of
Kim53DJ+P to counteract the lethality of Kim53pGFP was
substantial. It therefore appears that s.c infection with Kim53DJ+P
leads to the development of rapid systemic resistance against a
subcutaneous challenge that would otherwise kill the animal within
6 days.
Subcutaneous administration of Kim53DJ+P produces
rapid and effective systemic resistance against lethal
intravenous and intranasal challenges with a virulent Y.
pestis strain
We assessed the time window for the induction, duration and
extent of the systemic resistance generated by s.c administration of
Kim53DJ+P. The first series of experiments was based on
subcutaneous infection of mice with 1610
4 cfu of Kim53DJ+P,
followed by i.v. challenge at different times with ,65 LD50 of
Kim53pGFP (the septicemic model). Whereas all mice in the
control group (pretreated with saline) died within 3 days following
i.v. challenge, mice pretreated with s.c. inoculation of Kim53DJ+P
were protected in a time-dependent manner. Thus, 25%, 71% and
100% protection levels were observed at time intervals of 0, 24 and
72 hours, respectively (Figure 4C). It is noteworthy that even
simultaneous co-infection of Kim53DJ+P and the virulent
Kim53pGFP already provided a certain degree of protection,
and that pretreatment with Kim53DJ+P induced rapid and
complete protection within 3 days after inoculation.
Encouraged by these results, we then studied the scenario of
protection against airway infection (i.n. challenge), which serves as
a model of pneumonic plague. All control mice died within 5 days
after an i.n challenge with 6,000 cfu (,3LD50) of Kim53pGFP.
Relatively high protection levels were achieved in mice that were
challenged simultaneously (38% survival) or 72 hours (75%
survival) after s.c Kim53DJ+P pretreatment (Figure 4D; note that
in the intranasal experiments the ratio of Kim53DJ+Pt o
Kim53pGFP was only 2:1). Three days after s.c. inoculation of
the Kim53DJ+P cytotoxic strain, we could not detect any
development of antibodies against the highly immunogenic F1
antigen of Y. pestis.
Certain characteristics of Kim53DJ+P-induced resistance are
reminiscent of the cross-priming mechanism of CD8 T cell
activation [36–38]. To examine the involvement of CD8 T cells in
the protective mechanism induced by Kim53DJ+P, C57BL/6J
mice and their isogenic strain deleted for class I MHC genes
(K
bD
b2/2) were infected subcutaneously with the virulent
Kim53pGFP or the cytotoxic Kim53DJ+P strain (Figure 5E). All
mice infected with Kim53DJ+P survived the infection, whereas all
mice infected with Kim53pGFP died. This finding indicated that
the observed attenuation of the cytotoxic strain is not a result of a
cross-priming mechanism and CD8 T cell activation. In addition,
inflammatory processes in the spleen did not seem to account for
the rapid development of systemic protection, since no significant
differences could be demonstrated between the levels of pro-
inflammatory cytokines (TNF-a and IL-6) and Th1 cytokines
(IFN-c, IL-2 and IL-12) at 36, 60 and 72 hours post infection with
Kim53DJ+P or Kim53pGFP (data not shown).
Rapid induction of resistance by subcutaneous
administration of Kim53DJ+P does not interfere with the
development of long-term adaptive immunity
The possible consequences of the rapid induction of resistance
by Kim53DJ+P on the development of long-term humoral
immunity were studied. In these experiments, the Kim53DJ+P
strain simulated a vaccinating agent while the wild type Y. pestis
Kim53 served as a challenging agent. ELISA titers of anti-F1
antibodies served as a marker for the development of protective
long-lasting immunity. Results were compared to those obtained
in mice that had been vaccinated with the EV76 vaccine strain. In
the mouse model of bubonic plague, the assay conditions were
based on a single subcutaneous dose (1610
5 cfu) of Kim53DJ+Po r
EV76, followed by subcutaneous challenge with 1610
3 LD50 of Y.
pestis Kim53 45 days later. Mice injected with saline served as the
control group. Under these experimental conditions, the EV76
strain failed to elicit significant protective immunity, whereas all
mice vaccinated with Kim53DJ+P survived (Figure 5A). In the
mouse model of pneumonic plague, subcutaneous vaccination
with the Kim53DJ+P strain was followed 45 days later by i.n.
challenge with virulent Y. pestis Kim53. Under challenge with
5.5610
3 cfu, which is equivalent to about 15 LD50 (Figure 5B),
75% of the Kim53DJ+P-vaccinated mice survived, whereas all
control mice and mice vaccinated with the EV76 strain died.
ELISA titers of anti-F1 antibodies at 45 days after subcutaneous
infection with 1610
5 cfu of Kim53DJ+P ranged from 6,400 to
100,000, with a geometric mean of 23,000. Under the same
conditions of inoculation with EV76, the anti-F1 titers ranged
from below the limit of detection (,10) to 320, with a geometric
Figure 2. Kim53DJ+P is deficient in dissemination to target
organs and to the blood following subcutaneous infection.
Mice were infected subcutaneously with 1610
4 cfu of either
Kim53pGFP (black symbols) or Kim53DJ+P (white symbols). Animals
(4–5 per group) were sacrificed at 60 hours post-infection. Blood was
collected, and the draining inguinal lymph nodes (ILN) and spleens
were harvested, homogenized in 1 ml PBS and cultured on brain heart
infusion agar plates at 28uC for 48 hrs. Values in Figure represent total
bacterial loads in infected organs (cfu/organ), or bacterial concentration
in blood (cfu/ml). LOD, limit of detection. Horizontal bars represent the
average value of bacterial load in each case. Differences in bacterial
concentrations in blood and internal organs were analyzed by the non-
parametric Mann-Whitney test.
doi:10.1371/journal.pone.0005938.g002
Protection by Cytotoxic Y. pe
PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e5938mean of less than 30. Hence, rapid induction of resistance by
subcutaneous administration of Kim53DJ+P does not seem to
interfere with the induction of long-term adaptive immunity
against the plague. Rather, this route of exposure to Kim53DJ+P
appears to be a means for improved stimulation of long-term
adaptive immunity.
Discussion
The ability of bacterial pathogens to induce apoptosis in target
immune cells such as macrophages and neutrophils provides an
obvious advantage during infection, since these cells would
otherwise kill the pathogens. Nevertheless, under particular
circumstances, preventing apoptosis can provide a survival
advantage by allowing the bacteria to replicate inside a shielded
niche and eventually to be transported to target organs while
avoiding recognition by the immune system. Under such
circumstances, an effective mechanism of cell killing at the early
stages of infection would therefore be disadvantageous. Y. pestis has
long been considered to be a facultative intracellular pathogen
[1,39] and several studies have demonstrated that the pathogen
survives and replicates in macrophages both in vivo and in vitro
[31,33,40–45]. It is believed that Y. pestis replicates within
macrophages during the early stages of infection at peripheral
host sites, while extracellular growth is predominant during the
later stages of infection.
Y. pestis exploits a variety of mechanisms for evading or coping
with the host immune responses in the early stages of infection
Figure 3. Kim53DJ+P is highly virulent following systemic or airway infection. (A) Systemic infection (i.v. inoculation). Groups of 6 mice
were infected intravenously with a dose of 2610
3 cfu of Kim53pGFP (circle) or Kim53DJ+P (triangle), and mortality was monitored daily for 14 days.
(B) Airway infection (i.n. inoculation). Groups of 5 mice were infected intranasally with 6610
4 cfu of Kim53pGFP (circle) or Kim53DJ+P (triangle). (C)
Dissemination of Y. pestis strains to blood and internal organs following intranasal infection. Groups of 5 mice were infected intranasally with
2610
5 cfu of Kim53pGFP (black symbol) or Kim53DJ+P (white symbol) and sacrificed 48 hours post-infection. Bacterial concentration in blood and
total bacterial loads in lungs, mediastinal lymph nodes (MSLNs) and the spleen were determined as described in the legend to Figure 2.
doi:10.1371/journal.pone.0005938.g003
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to prevent the stimulation of LPS-induced inflammatory response
[46] and virulence mechanisms involving TTSS effectors and
other factors such as Pla [47].
The TTSS effector YopJ/P of Yersinia was shown to exert a
variety of adverse effects upon interaction with innate immune
cells, including induction of apoptotic cell death [6–8]. However,
our recent in vitro studies with the Y. pestis EV76 strain
demonstrated ineffective YopJ-mediated cytotoxicity of Y. pestis
in macrophages and dendritic cells, due to inefficient translocation
of the effector to target cells [10,26]. In contrast, YopP (the
homologue of YopJ) from Y. enterocolitica O:8 was shown to be
readily translocated into target cells and to exert high cytotoxic
activity. These features were also preserved when YopP was
expressed in a Y. pestis genetic background [10]. The essentiality of
YopJ/P functions for Yersinia virulence in vivo is not yet clear.
Studies on the involvement of YopJ in Y. pestis virulence indicated
that this effector was not essential for virulence in rodent models of
septicemic and bubonic plague [10,11,30]. Here we show that
YopJ is also not essential for virulence in the mouse model of
pneumonic plague, as reflected by the finding that a yopJ-deleted
Kim53 mutant fully retains its virulence upon intranasal
administration. We therefore assumed that the impaired cytotox-
icity of Y. pestis may rather contribute to virulence by restraining
YopJ translocation into phagocytic cells and thereby limiting the
ability to induce cell death, although the ability to suppress MAPK
phosphorylation and TNF-a secretion is retained [10].
To examine this hypothetical relationship between cytotoxicity
and virulence, we generated Y. pestis strains expressing YopP or
YopJ (Kim53DJ+P, Kim53DJ+J) and assessed their cytotoxic
activity and virulence in mouse models of plague disease,
comparing them to the control virulent Y. pestis strain
(Kim53pGFP). We show that Y. pestis carrying the expression
vector alone, the yopJ deletion mutant and the YopJ-expressing
strain (Kim53DJ+J) all exhibit low cytotoxic potency, and preserve
their virulence upon subcutaneous infection of mice (Figure 1D).
In contrast, the Kim53DJ+P strain appeared to acquire markedly
enhanced cytotoxic activity in its interaction with J774A.1
macrophage cells in vitro and in the tissue of infected mice
(Figure 1B, E and 2). Concomitant with this enhanced cytotoxicity,
the subcutaneously administered YopP-expressing Y. pestis strain
exhibited a dramatic decrease in virulence, as reflected by
elevation of the LD50 value from 1 cfu to more than 10
7 cfu.
The colonization of internal organs by the YopP-expressing Y.
pestis strain was substantially reduced (,100-fold decrease relative
to the control strain) and most significantly, bacteria could not be
detected at all in the blood (Figure 2). The mere presence of a high
load of plasmid copies or high levels of Yop effector (mediated by
their expression from the expression vector) could not account for
the observed attenuated phenotype, since the control strain
(Kim53pGFP) carrying the same vector load and the YopJ-
expressing strain (Kim53DJ+J) were highly virulent similar to the
wild-type Kim53 strain. In addition, extensive control experiments
indicated that expression of YopP did not affect the functionality
of TTSS, the bacterial growth rate or pYopP plasmid stability
(Figure 1A, C and Materials and Methods). It appears therefore
that an inverse relationship between YopP-induced cytotoxicity
and virulence upon infection via the subcutaneous route does exist.
A similar trend was recently reported for a recombinant Y.
pseudotuberculosis strain expressing Y. enterocolitica YopP, which
demonstrated impaired virulence in oral mouse infections [13].
Other examples of an inverse relationship between induction of
macrophage apoptosis and virulence were also demonstrated in
other pathogens such as Francisella tularensis [48] and Legionella
pneumophila [49].
It is quite striking however that the virulence of Kim53DJ+P was
preserved when it was inoculated via the intravenous and
intranasal routes of infection (Figure 3). These results may suggest
that the Kim53DJ+P strain is not genetically impaired either in its
virulence potential or in its ability to disseminate to various organs.
Rather, they emphasize the uniqueness of the subcutaneous mode
of infection for the manifestation of the Y. pestis attenuated
phenotype.
One possible explanation for this site-specific phenotypic
attenuation is that the subcutaneous administration of Kim53DJ+P
may induce a rapid immune protective response. This notion is
indeed supported by the studies of mixed subcutaneous infections
of a virulent Y. pestis strain and Kim53DJ+P. The cross-protection
provided by Kim53DJ+P was so effective that it could overcome
infection with at least 10
4 LD50 of the virulent strain (depending
on the cfu ratio of Kim53DJ+P to virulent Kim53pGFP; Figure 4A
and Table 2). Two possible mechanisms could account for this
cross-protection: a localized destruction of co-infected immune
cells leading to disruption of the propagation of Y. pestis,o r
alternatively induction of certain resistance mechanisms. The fact
that effective cross-protection could be mediated by subcutaneous
inoculation of Kim53DJ+P even when the co-infecting virulent
strain was administrated at a separate site supports the idea of
systemic protection (Figure 4B). Most striking was the observation
that effective cross-protection against intravenous and intranasal
lethal challenges of the virulent strain was acquired by subcuta-
neous administration of Kim53DJ+P (Figure 4C, D). Furthermore,
since the mean time to death of naı ¨ve mice infected intravenously
or intranasally with virulent Y. pestis is 3–4 days, it appears that the
protective response developed very rapidly. This was clearly
demonstrated when the cytotoxic Kim53DJ+P strain was admin-
istered 72 hours prior to the challenge with the virulent
Kim53pGFP strain.
The association between the enhanced apoptotic effect of
Kim53DJ+P and the rapidly acquired protection is reminiscent of
the proposed MHC-I-mediated cross-priming mechanism of CD8
T cell activation, which is initiated by pathogen-induced apoptosis
[36,50]. In this process, bacterial engulfment by macrophages
leads to the formation of apoptotic vesicles that contain bacterial
antigens. These vesicles are then engulfed and processed by
neighboring dendritic cells, leading downstream to the rapid
activation of CD8 T cells. However, our results show that the
Table 2. Protection conferred by Kim53DJ+P upon co-
infection of mice with virulent Kim53pGFP.
Bacterial
ratio Bacterial dose (cfu)
% Survival
(Live/Total)a
Kim53pGFP
b Kim53DJ+P
1:100 10 10
3 100 (5/5)
10
2 10
3 80 (4/5)
1:10 10
3 10
4 80 (4/5)
10
4 10
5 80 (4/5)
1:1 10
2 10
2 20 (1/5)
10
3 10
3 20 (1/5)
- 10 - 0 (0/5)
aMice were co-infected subcutaneously with mixtures of Kim53pGFP and
Kim53DJ+P in different bacterial ratios. Mortality was monitored for 14 days.
bOne colony forming unit is equivalent to 1 s.c. LD50.
doi:10.1371/journal.pone.0005938.t002
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infections of the virulent Kim53pGFP and various Y. pestis strains were administered at a single site. Groups of 5 mice were infected at a single site
located on the lower back with 1610
2 cfu of Kim53pGFP alone (circle); a mixture of 1610
2 cfu of Kim53pGFP with 1610
3 cfu of Kim53DJ+P (square);
1610
3 cfu of Kim53Dp10Dp70 (triangle); or 1610
3 cfu of Y. pestis pgm
2 EV76 strain (diamond). Mortality was monitored daily for 14 days (B).
Comparison of subcutaneous coinfection with Kim53DJ+P and Kim53pGFP administered at a single site (square) and at two separate sites (black
triangle). Mice were injected in their lower back with a mixture of Kim53pGFP (1610
2 cfu) and Kim53DJ+P( 3 610
3 cfu) for the single site. For the two
separate sites, 10 mice were injected in the upper back with 3610
3 cfu of Kim53DJ+P and immediately thereafter with 1610
2 cfu of Kim53pGFP in
the lower back. Control mice were injected in the lower back with 1610
2 cfu of Kim53pGFP (circle). (C) Subcutaneous infection of mice with
Kim53DJ+P followed by intravenous challenge with virulent Y. pestis. In total, 8 mice were injected subcutaneously in the lower back with 10
4 cfu of
Kim53DJ+P. Afterwards, 2610
3 cfu of the virulent Kim53pGFP were administered intravenously immediately (0 hr), or after 24 hrs or 72 hrs. Control
mice were only infected intravenously with Kim53pGFP (circle). (D) Subcutaneous infection of mice with Kim53DJ+P followed by intranasal challenge
with virulent Y. pestis. In total, 8 mice were injected subcutaneously with Kim53DJ+P as described in (C) and exposed intranasally to 6610
3 cfu
(,3LD50) of the virulent Kim53pGFP immediately (0 hr) or 72 hrs later. Mortality was monitored daily for 14 days. (E) Subcutaneous infections of
K
bD
b2/2 mice (class I MHC genes deleted) with 1610
3 cfu of Kim53pGFP (circle), 1610
3 cfu of Kim53DJ+P (open triangle) or 1610
4 cfu of Kim53DJ+P
(closed triangle).
doi:10.1371/journal.pone.0005938.g004
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upon subcutaneous infection of mice deleted for class I MHC
genes (K
bD
b2/2), indicating that CD8 T cell activation cannot
account for the dramatic attenuation of virulence in the
Kim53DJ+P strain. The mechanistic basis underlying the
enhancement of the rapid protective response by subcutaneous
administration of Kim53DJ+P therefore remains to be determined,
and is probably related to a combination of innate and adaptive
immunity.
Our data indicate that s.c. administration of Kim53DJ+P can
elicit a robust long-term immune response. This was demonstrated
by (a) development of 1,000-fold higher anti-F1 antibody titers
compared to those obtained by immunization with a similar dose
of the EV76 vaccine, and (b) ability to achieve considerably more
effective and long-lasting protective immunity compared to the
EV76 vaccine strain, in both the bubonic and pneumonic plague
mouse models (Fig. 5). Nevertheless, in spite of the observation
that EV76DJ+P is more cytotoxic to macrophages than EV76,
both strains are equally poor in their ability to elicit specific anti-F1
antibody response or to provide protection. These results suggest
that expression of YopP per se and its ability to confer extensive
cytotoxicity are not sufficient to explain the potent immune
response demonstrated by Kim53DJ+P. Irrespective of the actual
mechanisms of immunity, the observed development of rapid and
long-lasting immunity and the importance of the inoculation site
may have practical implications in the design of future Y. pestis
vaccines/therapies against pneumonic plague.
The downgraded translocation efficiency of YopJ may represent
an additional example of a virulence mechanism developed by Y.
pestis. Retention of YopJ expression in Y. pestis indicates that the
low amounts of protein translocated into target cells may still
provide a survival advantage to Y. pestis during in vivo infection
[10,11]. It is therefore tempting to speculate that the diminished
cytotoxicity of YopJ was evolved to fit the unique life cycle of Y.
pestis in nature. Thus, following the intra-dermal injection of Y.
pestis bacteria by fleas, the ineffective YopJ-mediated cytotoxicity
ensures evasion from the rapid induction of immune response,
which otherwise could prevent systemic infection (as is the case
when Y. pestis expresses YopP rather than the endogenous YopJ).
Obviously, the absence of bacteria in the blood will terminate the
Y. pestis cycle in nature since the vector fleas must feed on a
septicemic mammal.
Materials and Methods
Bacterial strains
Y. pestis strains used in this study are listed in Table 1. Plasmid
construction was based on replacing the GFP gene in pGFPuv
plasmid (Clontech) by yopP or yopJ genes of either Y. enterocolitica
O:8 or Y. pestis, respectively. Construction of the Kimberley53 yopJ
deletion mutant (Kim53DJ) was performed as described previously
[10]. The pGFPuv, pYopJ and pYopP plasmids were introduced
into Y. pestis strains by electroporation resulting in the generation
of Kim53pGFP, Kim53DJ+J and Kim53DJ+P strains, respectively.
These strains were routinely grown in heart infusion broth (HIB,
Difco) supplemented with 100 mg/ml ampicillin (Sigma, Israel).
The in vivo stability of pGFPuv, pYopJ and pYopP was examined
by plating bacteria recovered from the spleen and the draining
lymph nodes up to 7 days post infection, on nonselective and
selective plates (100 mg ampicillin, the antibiotic marker on
pGFPuv and its derivatives). All bacteria recovered from mice
infected with the Kim53pGFP, Kim53DJ+J or Kim53DJ+P strains
were found to be resistant to ampicillin. The Kim53 strain
carrying the pGFPuv plasmid (Kim53pGFP) demonstrated
comparable LD50 values and a mean-time-to-death (MTTD) to
the wild type strain via both s.c. and i.n. routes of infection and
served as a control strain. Genotype verification of all obtained
phenotypes was done by PCR and Western blot analyses using
rabbit anti-YopJ/P polyclonal antibodies [10]. All the strains used
in this study were tested and verified to carry the plasmids and
virulence markers pMT, pCD1, pPCP1 and the pgm locus.
Cell cultures
The murine macrophage-like cell line J774A.1 and the murine
alveolar macrophage cell line MH-S were obtained from ATCC.
The J774A.1 cells were grown at 37uC under 5% CO2 in DMEM
Figure 5. Y. pestis Kim53DJ+P strain confers prolonged protection against plague. (A) Mice (7–8 per group) were infected subcutaneously
with 1610
5 cfu of Kim53DJ+P (circle); EV76 (6symbol); or EV76DJ+P (triangle). Control animals were treated with saline (square). Animals were bled
for ELISA determination of anti-F1 antibody titers 45 days following immunization. Titers following immunization with Kim53DJ+P ranged from
64,000 to 100,000, with GMT of 18,500, while titers for the EV76 or EV76DJ+P immunized animals ranged from 640 to less than 10, with GMT of 30 and
10, respectively. Animals were challenged subcutaneously with 1610
3 cfu (,1610
3 LD50)o fY. pestis Kim53 (panel A) or intranasally with 8610
3 cfu
(,15 LD50)o fY. pestis Kim53 (panel B).
doi:10.1371/journal.pone.0005938.g005
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fetal calf serum (FCS), 1 mM sodium pyruvate, 4 mM L-
glutamine and 1% non essential amino acids. MH-S cells were
grown at 37uC under 5% CO2 in RPMI 1640 medium (Beit
Haemek, Israel) supplemented with 10% heat-inactivated FCS,
1 mM sodium pyruvate, 2 mM L-glutamine, 10 mM HEPES
(pH 7.3), 0.003% bicarbonate, 0.05 mM 2-mercaptoethanol.
Cell cytotoxicity assay
For infection of cultured cells, bacteria were grown by shaking for
18 hours at 28uC in HIB. The resulting cultures were diluted in HIB
medium to OD660 0.05 and allowed to grow for 3 hours at 37uCt o
induce Yops secretion [10]. Bacteria were harvested, washed once
and re-suspended in DMEM supplemented with 10% FCS and
added to the cells (2–6610
4 cells/well) at the indicated multiplicities
of infection (MOIs). Bacteria were impacted onto the cells by
centrifugation at 130 g for 5 min followed by incubation for
additional one hour at 37uC, 5% CO2. Gentamicin was then added
to the cultures to a final concentration of 50 mg/ml and the cultures
were thereafter incubated for additional 6 hours until harvesting.
Supernatants of infected macrophages were quantified colorimetri-
cally for released lactate dehydrogenase (LDH) using the Cytotox 96
non-radioactive cytotoxicity assay (Promega) according to the
manufacturer’s instructions. The absorbance (A490) was determined
using a microplate reader (Sunrise, Tecan). Cytotoxicity caused by
bacteria was expressed as % cell death. Percentage of cytotoxicity was
calculated using the formula: 1006[(experimental release–spontane-
ous release)/(maximum release–spontaneous release)]. The sponta-
neous release reflects the amount of LDH released from the
cytoplasm of uninfected macrophages, whereas the maximum release
is the amount of LDH released from detergent-lysed uninfected
macrophages.
Western blot analysis
Bacteria (5610
7) were lysed with Laemmli Sample buffer (Bio-
Rad) and subjected to 10% SDS-PAGE. After transfer to
nitrocellulose membranes, duplicate membranes were developed
with polyclonal rabbit anti-peptide YopP/J antibodies, which react
with both YopP and YopJ as described by Zauberman et al. [10]
or with polyclonal goat anti-YopE antibodies (bL-20, Santa Cruz
Biotechnology) followed by horseradish peroxidase (HRP) conju-
gated second antibody and then visualized by electrochemical
luminescence (ECL).
Antisera and serological tests
Mouse anti-F1 antibody titer determination was performed by
ELISA as described previously [51]. Briefly, microtiter plates were
coated with purified recombinant F1 antigen [52]. Tested sera were
serially diluted by 2-fold dilutions in a final volume of 50 mla n d
were incubated in the wells for 1 hour at 37uC. Alkaline
phosphatase–labeled rabbit anti-mouse IgG or goat anti-mouse
IgM (1/2500 dilution, Sigma) was used as the 2
nd layer. Titers were
defined as reciprocal values of the endpoint serum dilutions, which
displayedOD405valuestwofold higherthannormalserumcontrols.
Histology and immunohistochemistry
Formalin-fixed spleens were embedded in paraffin and 2 mm
sections were prepared. Apoptotic cells were then detected by
immunohistochemical staining using anti cleaved caspase-3
polyclonal antibodies (Cell signaling) and the Histostem SP kit
(Zymed), according to the manufacturer’s instructions.
Animal studies
All animal experiments were performed in accordance with the
Israeli law and were approved by the Ethics Committee for animal
experiments at the Israel Institute for Biological Research. Female
5–6 weeks old of OF1 mice (IFFA CREDO S.A., France),
C57BL/6J (Harlan, Israel) and K
bD
b2/2 (received from Prof. L.
Eisenbach, Weizmann institute, Israel) [53] were used in this
study. All in vivo experiments were carried out in OF1 mice,
unless otherwise noted. For subcutaneous (s.c.) and intravenous
(i.v.) infections of mice, Y. pestis bacteria were grown on brain heart
infusion agar (BHIA, Difco) for 48 hours at 28uC, suspended in
5 ml saline solution (0.9% NaCl), and then diluted in saline
solution to the required infection dose.
Bacteria were quantified by counting colony forming units after
plating and incubating on BHIA plates. In s.c. infections, samples
of 100 ml were administered into the mouse lower back. Under
these conditions the LD50 of the Kimberley53 strain is 1–3 cfu
[51]. In i.v. infections, samples of 50 ml were injected into the
mouse tail vein. For intranasal (i.n.) infections, Y. pestis strains were
grown on BHIA as above and then suspended in HIB medium
supplemented with 0.2% (+)Xylose (Sigma) and 2.5 mM CaCl2
(Sigma) to OD660 0.01 and incubated for additional 22 hrs at
28uC in a shaker (100 rpm). At the end of the incubation period
the cultures were washed, diluted in saline solution to the required
infection dose and quantified by cfu counting as described above.
Prior to infection, mice were anaesthetized with a mixture of 0.5%
Ketamine HCl and 0.1% Xylazine and then infected intranasally
with 35 ml/mouse of bacterial suspension. The intranasal LD50 of
the Kimberley53 strain under these conditions is ca. 550 cfu. LD50
values were calculated according to the method described by Reed
and Muench [54]. Mann-Whitney test was used to analyze
significant differences in time to death and was complemented by
the Log-rank test as a means to compare animal survival curves.
For bacterial dissemination to internal organs and blood, groups of
4–5 mice were anaesthetized, tail vein blood was collected and
spleens, draining inguinal lymph nodes, lungs and mediastinal lymph
nodes were then harvested and tissue homogenates were prepared in
1 ml PBS/organ. Bacterial enumeration in tissue homogenates or in
blood samples was done by plating serial dilutions in PBS on BHIA
and calculating cfu/organ or cfu/1 ml blood. Determination of
TNF-a,I L - 6 ,I F N c,I L - 2a n dI L - 1 2c o n c e n t r a t i o n si no r g a n s
homogenates was performed by enzyme-linked immunosorbent
assays using the mouse Duo Set kit (R&D systems). Differences in
cytokines and bacterial concentrations in blood and internal organs
were analyzed by the non-parametric Mann-Whitney test.
Acknowledgments
We thank Mr. Gur David, Mr. Aftalion Moshe, and Mrs. Shirley Lazar for
their excellent technical assistance. We thank Dr. Velan Baruch and Dr.
Ariel Naomi for critical reading of this manuscript.
Author Contributions
Conceived and designed the experiments: AZ EBH AS EM. Performed the
experiments: AZ AT YL EM. Analyzed the data: AZ GH YF SC AS EM.
Wrote the paper: AZ GH AS EM.
References
1. Perry R, Fetherston J (1997) Yersinia pestis-etiologic agent of plague. Clin
Microbiol Rev 10: 35–66.
2. Cornelis GR (2002) Yersinia type III secretion: send in the effectors. The journal
of Cell Biology 158: 401–408.
Protection by Cytotoxic Y. pe
PLoS ONE | www.plosone.org 10 June 2009 | Volume 4 | Issue 6 | e59383. Marketon MM, DePaolo RW, DeBord KL, Jabri B, Schneewind O (2005)
Plague bacteria target immune cells during infection. Science 309: 1739–1741.
4. Mota LJ, Cornelis GR (2005) The bacterial injection kit: type III secretion
systems. Ann Med 37: 234–249.
5. Viboud GI, Bliska JB (2005) Yersinia outer proteins: role in modulation of host
cell signaling responses and pathogenesis. Annu Rev Microbiol 59: 69–89.
6. Mills S, Boland A, Sory M, van der Smissen P, Kerbourch C, et al. (1997)
Yersinia enterocolitica induces apoptosis in macrophages by a process requiring
functional type III secretion and translocation mechanisms and involving YopP,
presumably acting as an effector protein. Proc Natl Acad Sci U S A 94:
12638–12643.
7. Monack D, Mecsas J, Ghori N, Falkow S (1997) Yersinia signals macrophages to
undergo apoptosis and YopJ is necessary for this cell death. Proc Natl Acad
Sci U S A 94: 10385–10390.
8. Ruckdeschel K, Roggenkamp A, Lafont V, Mangeat P, Heesemann J, et al.
(1997) Interaction of Yersinia enterocolitica with macrophages leads to macrophage
cell death through apoptosis. Infect Immun 65: 4813–4821.
9. Weeks S, Hill J, Friedlander A, Welkos S (2002) Anti-V antigen antibody
protects macrophages from Yersinia pestis - induced cell death and promotes
phagocytosis. Microb Pathog 32: 227–237.
10. Zauberman A, Cohen S, Mamroud E, Flashner Y, Tidhar A, et al. (2006)
Interaction of Yersinia pestis with macrophages: limitations in YopJ-dependent
apoptosis. Infect Immun 74: 3239–3250.
11. Lemaitre N, Sebbane F, Long D, Joseph Hinnebusch B (2006) Yersinia pestis YopJ
Suppresses Tumor Necrosis Factor Alpha Induction and Contributes to
Apoptosis of Immune Cells in the Lymph Node but Is Not Required for
Virulence in a Rat Model of Bubonic Plague. Infect Immun 74: 5126–5131.
12. Monack DM, Mecsas J, Bouley D, Falkow S (1998) Yersinia-induced apoptosis in
vivo aids in the establishment of a systemic infection of mice. J Exp Med 188:
2127–2137.
13. Brodsky IE, Medzhitov R (2008) Reduced secretion of YopJ by Yersinia limits in
vivo cell death but enhances bacterial virulence. PLoS Pathog 4: e1000067.
14. Ruckdeschel K, Harb S, Roggenkamp A, Hornef M, Zumbihl R, et al. (1998)
Yersinia enterocolitica impairs activation of transcription factor NF-kappaB:
involvement in the induction of programmed cell death and in the suppression
of the macrophage tumor necrosis factor alpha production. J Exp Med 187:
1069–1079.
15. Schesser K, Spiik A, Dukuzumuremyi J, Neurath M, Pettersson S, et al. (1998)
The yopJ locus is required for Yersinia-mediated inhibition of NF-kappaB
activation and cytokine expression: YopJ contains aeukaryotic SH2-like domain
that is essential for its repressive activity. Mol Microbiol 28: 1067–1079.
16. Ruckdeschel K, Machold J, Roggenkamp A, Schubert S, Pierre J, et al. (1997)
Yersinia enterocolitica promotes deactivation of macrophage mitogen-activated
protein kinases extracellular signal-regulated kinase-1/2, p38, and c-Jun NH2-
terminal kinase. Correlation with its inhibitory effect on tumor necrosis factor-
alpha production. J Biol Chem 272: 15920–15927.
17. Palmer LE, Hobbie S, Galan JE, Bliska JB (1998) YopJ of Yersinia pseudotuberculosis
is required for the inhibition of macrophage TNF-alpha production and
downregulation of the MAP kinases p38 and JNK. Mol Microbiol 27: 953–965.
18. Boland A, Cornelis G (1998) Role of YopP in suppression of tumor necrosis
factor alpha release by macrophages during Yersinia infection. Infect Immun 66:
1878–1884.
19. Denecker G, Declercq W, Geuijen CA, Boland A, Benabdillah R, et al. (2001)
Yersinia enterocolitica YopP-induced apoptosis of macrophages involves the
apoptotic signaling cascade upstream of bid. J Biol Chem 276: 19706–19714.
20. Lilo S, Zheng Y, Bliska JB (2008) Caspase-1 activation in macrophages infected
with Yersinia pestis KIM requires the type III secretion system effector YopJ.
Infect Immun 76: 3911–3923.
21. Orth K, Xu Z, Mudgett MB, Bao ZQ, Palmer LE, et al. (2000) Disruption of
signaling by Yersinia effector YopJ, a ubiquitin-like protein protease. Science 290:
1594–1597.
22. Zhou H, Monack DM, Kayagaki N, I. W, Yin J, et al. (2005) Yersinia virulence
factor YopJ acts as a deubiquitinase to inhibit NF-kB activation. The Journal of
Experimental Medicine 202: 1327–1332.
23. Mittal R, Peak-Chew SY, McMahon HT (2006) Acetylation of MEK2 and I
kappa B kinase (IKK) activation loop residues by YopJ inhibits signaling. Proc
Natl Acad Sci U S A 103: 18574–18579.
24. Mukherjee S, Keitany G, Li Y, Wang Y, Ball HL, et al. (2006) Yersinia YopJ
acetylates and inhibits kinase activation by blocking phosphorylation. Science
312: 1211–1214.
25. Zauberman A, Velan B, Mamroud E, Flashner Y, Shafferman A, et al. (2007)
Disparity between Yersinia pestis and Yersinia enterocolitica O:8 in YopJ/YopP-
dependent functions. Adv Exp Med Biol 603: 312–320.
26. Velan B, Bar-Haim E, Zauberman A, Mamroud E, Shafferman A, et al. (2006)
Discordance in the effects of Yersinia pestis on dendritic cell functions: induction of
maturation and paralysis of migration. Infect Immun 74: 6365–6376.
27. Erfurth SE, Grobner S, Kramer U, Gunst DS, Soldanova I, et al. (2004) Yersinia
enterocolitica induces apoptosis and inhibits surface molecule expression and
cytokine production in murine dendritic cells. Infect Immun 72: 7045–7054.
28. Trulzsch K, Sporleder T, Igwe EI, Russmann H, Heesemann J (2004)
Contribution of the major secreted yops of Yersinia enterocolitica O:8 to
pathogenicity in the mouse infection model. Infect Immun 72: 5227–5234.
29. Galyov EE, Hakansson S, Wolf-Watz H (1994) Characterization of the operon
encoding the YpkA Ser/Thr protein kinase and the YopJ protein of Yersinia
pseudotuberculosis. J Bacteriol 176: 4543–4548.
30. Straley SC, Bowmer WS (1986) Virulence genes regulated at the transcriptional
level by Ca2+ in Yersinia pestis include structural genes for outer membrane
proteins. Infect Immun 51: 445–454.
31. Cavanaugh DC, Randall R (1959) The role of multiplication of Pasteurella pestis in
mononuclear phagocytes in the pathogenesis of flea-borne plague. J Immunol
83: 348–363.
32. Lukaszewski RA, Kenny DJ, Taylor R, Rees DG, Hartley MG, et al. (2005)
Pathogenesis of Yersinia pestis infection in BALB/c mice: effects on host
macrophages and neutrophils. Infect Immun 73: 7142–7150.
33. Pujol C, Bliska JB (2003) The ability to replicate in macrophages is conserved
between Yersinia pestis and Yersinia pseudotuberculosis. Infect Immun 71: 5892–5899.
34. Honko AN, Sriranganathan N, Lees CJ, Mizel SB (2006) Flagellin is an effective
adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.
Infect Immun 74: 1113–1120.
35. Lathem WW, Crosby SD, Miller VL, Goldman WE (2005) Progression of
primary pneumonic plague: a mouse model of infection, pathology, and
bacterial transcriptional activity. Proc Natl Acad Sci U S A 102: 17786–17791.
36. Winau F, Weber S, Sad S, de Diego J, Hoops SL, et al. (2006) Apoptotic vesicles
crossprime CD8 T cells and protect against tuberculosis. Immunity 24: 105–117.
37. Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from
apoptotic cells and induce class I-restricted CTLs. Nature 392: 86–89.
38. Yrlid U, Wick MJ (2000) Salmonella-induced apoptosis of infected macrophages
results in presentation of a bacteria-encoded antigen after uptake by bystander
dendritic cells. J Exp Med 191: 613–624.
39. Brubaker RR (1991) Factors promoting acute and chronic diseases caused by
Yersiniae. Clin Microbiol Rev 4: 309–324.
40. Charnetzky WT, Shuford WW (1985) Survival and growth of Yersinia pestis
within macrophages and an effect of the loss of the 47-megadalton plasmid on
growth in macrophages. Infect Immun 47: 234–241.
41. Finegold MJ (1969) Pneumonic plague in monkeys. An electron microscopic
study. Am J Pathol 54: 167–185.
42. Janssen WA, Surgalla MJ (1969) Plague bacillus: survival within host phagocytes.
Science 163: 950–952.
43. Straley SC, Harmon PA (1984) Growth in mouse peritoneal macrophages of
Yersinia pestis lacking established virulence determinants. Infect Immun 45:
649–654.
44. Oyston PC, Dorrell N, Williams K, Li SR, Green M, et al. (2000) The response
regulator PhoP is important for survival under conditions of macrophage-
induced stress and virulence in Yersinia pestis. Infect Immun 68: 3419–3425.
45. Pujol C, Bliska JB (2005) Turning Yersinia pathogenesis outside in: subversion of
macrophage function by intracellular yersiniae. Clin Immunol 114: 216–226.
46. Montminy SW, Khan N, McGrath S, Walkowicz MJ, Sharp F, et al. (2006)
Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide
response. Nat Immunol 7: 1066–1073.
47. Lathem WW, Price PA, Miller VL, Goldman WE (2007) A plasminogen-
activating protease specifically controls the development of primary pneumonic
plague. Science 315: 509–513.
48. Weiss DS, Brotcke A, Henry T, Margolis JJ, Chan K, et al. (2007) In vivo
negative selection screen identifies genes required for Francisella virulence. Proc
Natl Acad Sci U S A 104: 6037–6042.
49. Derre I, Isberg RR (2004) Macrophages from mice with the restrictive Lgn1
allele exhibit multifactorial resistance to Legionella pneumophila. Infect Immun 72:
6221–6229.
50. Winau F, Kaufmann SH, Schaible UE (2004) Apoptosis paves the detour path
for CD8 T cell activation against intracellular bacteria. Cell Microbiol 6:
599–607.
51. Flashner Y, Mamroud E, Tidhar A, Ber R, Aftalion M, et al. (2004) Generation
of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of
novel vaccine candidates. Infect Immun 72: 908–915.
52. Holzman T, Levy Y, Marcus D, Flashner Y, Mamroud E, et al. (2006)
Production and purification of high molecular weight oligomers of Yersinia pestis
F1 capsular antigen released by high cell density culture of recombinant
Escherichia coli cells carrying the caf1 operon. Microbial cell factories 5: 98.
53. Vugmeyster Y, Glas R, Perarnau B, Lemonnier FA, Eisen H, et al. (1998) Major
histocompatibility complex (MHC) class I K
bD
b2/2 deficient mice possess
functional CD8+ T cells and natural killer cells. Proc Natl Acad Sci U S A 95:
12492–12497.
54. Reed LJ, Muench H (1938) A simple method of estimating fifty per cent
endpoints. Am J Hyg 27: 493–497.
55. Grosfeld H, Cohen S, Bino T, Flashner Y, Ber R, et al. (2003) Effective
protective immunity to Yersinia pestis infection conferred by DNA vaccine coding
for derivatives of the F1 capsular antigen. Infect Immun 71: 374–383.
56. Ben-Gurion R, Shafferman A (1981) Essential virulence determinants of
different Yersinia species are carried on a common plasmid. Plasmid 5: 183–187.
Protection by Cytotoxic Y. pe
PLoS ONE | www.plosone.org 11 June 2009 | Volume 4 | Issue 6 | e5938